Matrix-degrading metalloproteinases in tumor progression.
The matrix-degrading metalloproteinases (MMPs) have been implicated in tumor invasion and metastasis. Recently it has become clear that the expression of MMPs in tumors is frequently localized to stromal cells surrounding malignant tumor cells. In the mouse skin model of multi-stage carcinogenesis, the MMP stromelysin is expressed in stromal fibroblast-like cells surrounding benign and malignant squamous cell carcinomas. Conversion of these tumors to highly invasive and metastatic spindle-cell tumors is however, associated with the expression of stromelysin-1 mRNA in the tumor cells themselves. The analysis of MMPs in human colon adenocarcinomas at different stages of tumor progression revealed that matrilysin was the only MMP expressed in the tumor cells, while stromelysin-1 and stromelysin-3 mRNA was detected in stromal cells surrounding malignant tumor cells. Matrilysin mRNA is detected in benign tumors as well as malignant tumor cells, and the relative level and percent of tumors expressing matrilysin correlates with the stage of tumor progression. These results suggest that both stromal and tumor cell metalloproteinases may contribute to tumor invasion and metastasis, and also suggests that MMPs may play a role in earlier events in the tumor progression pathway. A potential role for MMPs in tumor growth is illustrated by results which suggest that the expression of matrilysin in human colon cancer-derived cells increases tumorigenicity following injection into the cecum, and that transgenic mice expressing matrilysin mRNA show a marked proliferative response. MMPs may therefore play multiple roles in tumor progression.
Matrisian
L M
LM
Department of Cell Biology, Vanderbilt University, Nashville, TN 37232, USA.
Wright
J
J
Newell
K
K
Witty
J P
JP
D000230:Adenocarcinoma / Q000201:enzymology / Q000473:pathology; D000818:Animals; D001485:Basement Membrane / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced / Q000201:enzymology / Q000473:pathology; D003043:Cocarcinogenesis; D003110:Colonic Neoplasms / Q000201:enzymology / Q000473:pathology; D018450:Disease Progression; D016326:Extracellular Matrix Proteins / Q000378:metabolism*; D006801:Humans; D019278:Matrix Metalloproteinase 3 / Q000096:biosynthesis / Q000235:genetics; D020783:Matrix Metalloproteinase 7; D008666:Metalloendopeptidases / Q000145:classification / Q000235:genetics / Q000502:physiology*; D051379:Mice; D008822:Mice, Transgenic; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009362:Neoplasm Metastasis / Q000473:pathology*; D009363:Neoplasm Proteins / Q000145:classification / Q000502:physiology*; D009369:Neoplasms / Q000201:enzymology* / Q000473:pathology; D012333:RNA, Messenger / Q000378:metabolism; D012334:RNA, Neoplasm / Q000378:metabolism; D012878:Skin Neoplasms / Q000139:chemically induced / Q000201:enzymology / Q000473:pathology
D016326:Extracellular Matrix Proteins; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D008666:Metalloendopeptidases; D019278:Matrix Metalloproteinase 3; D020783:Matrix Metalloproteinase 7